• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Icon reports second quarter 2013 revenue of $334 million

Icon reports second quarter 2013 revenue of $334 million

July 26, 2013
CenterWatch Staff

CRO Icon said net revenues grew 21% to $334.2 million in the second quarter ended June 30, from $277 million in the year-ago quarter. Revenue in the first half of 2013 rose 23% to $651 million, from $529 million a year ago.

Income from operations in the first half of 2013 was $58.3 million, or 9% of revenue, compared with $28.4 million or 5.4% of revenue in the first half of 2012. Income from operations was $30.9 million, or 9.3% of revenue, compared to $16.6 million, or 6% of revenue, in the year-ago quarter. Net income was $26.5 million, up from $12.9 million a year ago. Net income for the first half of 2013 was $48.7 million, compared with $21.9 million in 2012.

Guidance for 2013 has been updated, with revenue expected to be in the range of $1.3 billion to $1.32 billion, and earnings-per-share in the $1.54 to $1.64 range.

Cash generated from operating activities was $10.8 million, after expenditure of $26 million on prior period acquisition earn outs and capital expenditure of $7.8 million. The company’s net cash amounted to $184 million at the end of the second quarter, compared to net cash of $190 million on Dec. 31, 2012. 

During the quarter, the company recorded a charge of $4.6 million for various restructuring costs. U.S. GAAP income from operations after these items amounted to $26 million, or 7.9% of revenue. U.S. GAAP net income for the quarter was $22 million, or 36 cents per share.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing